Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea

Current Medical Research and Opinion

Volumn 32, Issue 6, 2016, Pages 1131-1136

  Xiaoyan, Chen ^a   Jing, Wang ^a   Xiaochun, Huang ^a   Yuyu, Tan ^a   Shunyou, Deng ^a   Yingyu, Fu ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute glucose fluctuation; CGMS; Chinese type 2 diabetes mellitus; DPP 4 inhibitors

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NITRILE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLISTER; CHINESE; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCALP PRURITUS; AGED; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; METABOLISM; PROSPECTIVE STUDY;

ADAMANTANE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; PYRROLIDINES; SULFONYLUREA COMPOUNDS;

EID: 84961392803     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2016.1162773     Document Type: Article

References (26)

1. Meng X, Gong C, Cao B, et al. Glucose fluctuations in association with oxidative stress among children with type 1 diabetes mellitus: comparison of different phases. J Clin Endocrinol Metab 2015;100:1828-36
2. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-54
3. Kurtz P, Claassen J, Helbok R, et al. Systemic glucose variability predicts cerebral metabolic distress and mortality after subarachnoid hemorrhage: a retrospective observational study. Crit Care 2014;18:R89
4. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014;37:2359-65
5. Hermanides J, Vriesendorp TM, Bosman RJ, et al. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838-42
6. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009;23:479-86
7. He YL, Wang Y, Bullock JM. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633-41
8. Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33: 1005-22
9. Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191-6
10. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011;13:775-83
11. Yamazaki M, Hasegawa G, Majima S, et al. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers. Diabetol Metab Syndr 2014;6:54
12. Chinese Diabetes Society. China guideline for type 2 diabetes (2013). Chin J Diabetes Mellitus 2014;7:447-98
13. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-82
14. Guerci B, Monnier L, Serusclat P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Obes Metab 2012;38:359-66
15. Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012;11:92
16. Johnson EL. Glycemic variability: too often overlooked in type 2 diabetes? Fam Pract 2010,59:E1-8
17. Mori Y, Taniguchi Y, Miyazaki S, et al. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther 2013;15:237-40
18. Yoshioka K, Isotani H, Ohashi S, et al. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy. Diabetes Metab Syndr 2013;7:32-4
19. He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab 2013;15:1111-19
20. Li CJ, Liu XJ, Bai L, et al. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr 2014;6:69
21. Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab 2014;16:443-50
22. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012;14:1061-72
23. Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and SUs – a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014;30: 241-56
24. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33:1609-29
25. Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013;8:419-30
26. Rosenstock J, Gross JL, Salinas CAA, et al. Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes. Diabetes 2011;60:A298